Lead Product(s) : VS-01
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : HealthCare Royalty
Deal Size : $201.7 million
Deal Type : Financing
Genfit Completes Royalty Financing with HCRx & Repurchase Offer Results
Details : The financing aims to advance the company's product pipeline including VS-01, an investigational drug based on a proprietary scavenging liposomal technology. It is treated in patients with ACLF.
Product Name : VS-01
Product Type : Other Small Molecule
Upfront Cash : $141.2 million
March 20, 2025
Lead Product(s) : VS-01
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : HealthCare Royalty
Deal Size : $201.7 million
Deal Type : Financing
Lead Product(s) : VS-01
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : HealthCare Royalty
Deal Size : $189.5 million
Deal Type : Financing
GENFIT Announces Royalty Financing, Debt Overhang Resolution Plan
Details : The company will use the proceeds to develop its pipeline focused on Acute-on-Chronic Liver Failure (ACLF), including VS-01, a first-in-class innovative liposomal-based therapeutic product.
Product Name : VS-01
Product Type : Other Small Molecule
Upfront Cash : $133.2 million
January 30, 2025
Lead Product(s) : VS-01
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : HealthCare Royalty
Deal Size : $189.5 million
Deal Type : Financing
Lead Product(s) : Lanifibranor,Empagliflozin
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Inventiva Reports Positive Phase II Results Combining Lanifibranor with Empagliflozin
Details : IVA337 (lanifibranor) is an orally-available small molecule activating all three PPAR isoforms, under evaluation for treating Nonalcoholic Steatohepatitis and Type 2 Diabetes.
Product Name : IVA337
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 18, 2024
Lead Product(s) : Lanifibranor,Empagliflozin
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Deuterated Pioglitazone
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Poxel to Present DESTINY-1 Phase 2 Results for PXL065 in NASH at AASLD The Liver Meeting® 2022
Details : PXL065 is a novel, proprietary deuterium-stabilized R-pioglitazone. PXL065 was observed to be safe and well tolerated with no dose-dependent increase in body weight and no increased lower extremity edema vs. placebo.
Product Name : PXL065
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 10, 2022
Lead Product(s) : Deuterated Pioglitazone
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Deuterated Pioglitazone
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PXL065 (deuterated pioglitazone) Phase 2 trial for the treatment of NASH met its primary efficacy endpoint for liver fat content reduction at 36-weeks for all doses.
Product Name : PXL065
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 22, 2022
Lead Product(s) : Deuterated Pioglitazone
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lanifibranor,Empagliflozin
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Phase IIb has demonstrated that IVA337 (lanifibranor) as a monotherapy could not only resolve NASH and improve fibrosis but also improve lipids and glycemic profiles, in combination with empagliflozin provide additional benefits and further improve cardi...
Product Name : IVA337
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 03, 2022
Lead Product(s) : Lanifibranor,Empagliflozin
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lanifibranor,Empagliflozin
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IVA337 (lanifibranor), orally-available small molecule that acts to induce anti-fibrotic, anti-inflammatory, beneficial vascular and metabolic changes in body by activating all PPAR isoforms, which are well‑characterized nuclear receptor proteins that ...
Product Name : IVA337
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 07, 2022
Lead Product(s) : Lanifibranor,Empagliflozin
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lanifibranor,Empagliflozin
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Lanifibranor, a pan-PPAR agonist, improves markers of cardiometabolic health in patients with NASH, has demonstrated beneficial effects on liver histology, NASH resolution and fibrosis improvement in patients.
Product Name : IVA337
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 04, 2022
Lead Product(s) : Lanifibranor,Empagliflozin
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nitazoxanide
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
GENFIT Provides Pipeline Update and Launch of New Clinical Programs
Details : GENFIT is launching a clinical program with nitazoxanide (NTZ) in this disease. A Phase 1 study to evaluate pharmacokinetics and pharmacodynamics in patients with varying degrees of hepatic impairment is expected to start in 4Q21 with clinical data expec...
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
November 05, 2021
Lead Product(s) : Nitazoxanide
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lanifibranor
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IVA337 (lanifibranor) is next generation pan-PPAR (peroxisome proliferator-activated receptors) agonist addressing pathophysiology of NASH (Non-alcoholic steatohepatitis) or in the treatment of, liver steatosis and moderate to severe necroinflammation wi...
Product Name : IVA337
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 20, 2021
Lead Product(s) : Lanifibranor
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable